NEW YORK (TheStreet) -- Merck (MRK) provided full-year earnings guidance in the range of $3.29 to $3.39 a share, excluding certain items, and reaffirmed its target of high single-digit comparable earnings per share compound annual growth rate from 2009 to 2013, after topping consensus estimates for the second quarter.

Analysts, on average, expect full-year earnings of $3.37 a share on revenue of $45.69 billion.

Merck reported second-quarter earnings of $752.4 million, or 24 cents a share, vs. $1.56 billion, or 74 cents a, share the previous year. Excluding items such as purchase accounting adjustments, merger-related expenses, restructuring costs and a gain on AstraZeneca's asset option exercise, second-quarter earnings were 86 cents a share vs. 83 cents the previous year.

The Wall Street consensus estimate for Merck's second quarter was earnings of 83 cents a share on revenue of $11.45 billion.

Merck shares were lower by 0.7% to $34.80 in premarket trading.

>>Search for Highest Dividends by Rate or Yield

Total sales for the quarter were $11.346 billion, up 92%. The company said it saw strong performance in pharmaceutical products, consumer care and animal health during the quarter.
More on Earnings
Today's Top Earnings
Earnings Calendar

-- Reported by Andrea Tse in New York

Get more stock ideas and investing advice on our sister site, Stockpickr.com.

Follow Andrea Tse on Twitter and become a fan on Facebook.

Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

More from Stocks

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

TheStreet's Top Columnists Take Your Questions on What Stocks to Buy

TheStreet's Top Columnists Take Your Questions on What Stocks to Buy

Is Tesla Really Being Sabotaged?

Is Tesla Really Being Sabotaged?

Beware of the Coming Economic Debt Bomb

Beware of the Coming Economic Debt Bomb